JP7085990B2 - クロロトキシンドメインを含むキメラ抗原レセプター - Google Patents

クロロトキシンドメインを含むキメラ抗原レセプター Download PDF

Info

Publication number
JP7085990B2
JP7085990B2 JP2018519030A JP2018519030A JP7085990B2 JP 7085990 B2 JP7085990 B2 JP 7085990B2 JP 2018519030 A JP2018519030 A JP 2018519030A JP 2018519030 A JP2018519030 A JP 2018519030A JP 7085990 B2 JP7085990 B2 JP 7085990B2
Authority
JP
Japan
Prior art keywords
cells
domain
modified
cltx
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018519030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531015A (ja
JP2018531015A6 (ja
Inventor
バリッシュ，マイケル
イー． ブラウン，クリスティーン
スティーブン ジェイ． フォーマン
ワン，ドンルイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2018531015A publication Critical patent/JP2018531015A/ja
Publication of JP2018531015A6 publication Critical patent/JP2018531015A6/ja
Priority to JP2022007016A priority Critical patent/JP7331162B2/ja
Application granted granted Critical
Publication of JP7085990B2 publication Critical patent/JP7085990B2/ja
Priority to JP2023129665A priority patent/JP7674425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/405—Invertebrates antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018519030A 2015-10-13 2016-10-13 クロロトキシンドメインを含むキメラ抗原レセプター Active JP7085990B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007016A JP7331162B2 (ja) 2015-10-13 2022-01-20 クロロトキシン領域を含むキメラ抗原受容体
JP2023129665A JP7674425B2 (ja) 2015-10-13 2023-08-09 クロロトキシン領域を含むキメラ抗原受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241021P 2015-10-13 2015-10-13
US62/241,021 2015-10-13
PCT/US2016/056901 WO2017066481A1 (en) 2015-10-13 2016-10-13 Chimeric antigen receptors containing a chlorotoxin domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022007016A Division JP7331162B2 (ja) 2015-10-13 2022-01-20 クロロトキシン領域を含むキメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2018531015A JP2018531015A (ja) 2018-10-25
JP2018531015A6 JP2018531015A6 (ja) 2018-12-13
JP7085990B2 true JP7085990B2 (ja) 2022-06-17

Family

ID=57233854

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018519030A Active JP7085990B2 (ja) 2015-10-13 2016-10-13 クロロトキシンドメインを含むキメラ抗原レセプター
JP2022007016A Active JP7331162B2 (ja) 2015-10-13 2022-01-20 クロロトキシン領域を含むキメラ抗原受容体
JP2023129665A Active JP7674425B2 (ja) 2015-10-13 2023-08-09 クロロトキシン領域を含むキメラ抗原受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022007016A Active JP7331162B2 (ja) 2015-10-13 2022-01-20 クロロトキシン領域を含むキメラ抗原受容体
JP2023129665A Active JP7674425B2 (ja) 2015-10-13 2023-08-09 クロロトキシン領域を含むキメラ抗原受容体

Country Status (12)

Country Link
US (2) US11230577B2 (enExample)
EP (2) EP3985027A1 (enExample)
JP (3) JP7085990B2 (enExample)
KR (1) KR20180056780A (enExample)
CN (1) CN108368159A (enExample)
CA (1) CA3001833A1 (enExample)
DK (1) DK3362470T3 (enExample)
ES (1) ES2902987T3 (enExample)
IL (2) IL302560B2 (enExample)
PL (1) PL3362470T3 (enExample)
PT (1) PT3362470T (enExample)
WO (1) WO2017066481A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL287889B2 (en) 2016-02-05 2024-03-01 Hope City Administration of engineered t cells for treatment of cancers in the central nervous system
AU2017355504C1 (en) 2016-11-04 2024-06-20 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
BR112019011277A2 (pt) 2016-12-02 2019-10-22 University Of Southern California polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
CN110352197B (zh) * 2016-12-09 2024-02-02 Uab研究基金会 嵌合氯毒素受体
WO2019084018A1 (en) * 2017-10-23 2019-05-02 City Of Hope CAR FOR THE TREATMENT OF HIV INFECTION
JP2020103675A (ja) * 2018-12-28 2020-07-09 株式会社三洋物産 遊技機
JP2020103677A (ja) * 2018-12-28 2020-07-09 株式会社三洋物産 遊技機
JP2020108444A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
JP2020108446A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
JP2020103676A (ja) * 2018-12-28 2020-07-09 株式会社三洋物産 遊技機
JP2020103674A (ja) * 2018-12-28 2020-07-09 株式会社三洋物産 遊技機
JP2020108442A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
JP2020108441A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
JP2020108443A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
JP2020103673A (ja) * 2018-12-28 2020-07-09 株式会社三洋物産 遊技機
JP2020108445A (ja) * 2018-12-28 2020-07-16 株式会社三洋物産 遊技機
US20220195060A1 (en) * 2019-04-05 2022-06-23 2Seventy Bio, Inc. Manufacturing anti-bcma car t cells
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
US20230374085A1 (en) * 2020-03-11 2023-11-23 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
EP4271702B1 (en) 2020-12-30 2024-11-06 VRG Therapeutics Zrt. Chlorotoxin derivatives and use thereof
KR20230134134A (ko) * 2021-01-20 2023-09-20 인8바이오 인코포레이티드 다가 클로로톡신 키메라 항원 수용체
US20240366662A1 (en) 2021-03-30 2024-11-07 City Of Hope Car t cell therapy and ifn gamma
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
WO2023092733A1 (zh) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 一种用于有效递送核酸的环状多肽载体及其变化形式
CN114014941B (zh) * 2022-01-10 2022-04-12 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
JP2025508371A (ja) * 2022-02-11 2025-03-26 フレッド ハッチンソン キャンサー センター Ｓｔｅａｐ１に結合するキメラ抗原受容体
US20250368958A1 (en) * 2022-06-14 2025-12-04 Purdue Research Foundation Car-expressing pluripotent stem cell-derived neutrophils loaded with drug nanoparticles and uses thereof
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物
WO2015105522A1 (en) 2014-01-13 2015-07-16 Forman Stephen J Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339683T3 (es) * 2004-04-06 2010-05-24 Transmolecular, Inc. Diagnostico y tratamiento de canceres de celulas mieloides y linfoides.
CN100564517C (zh) * 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
EP3444333A1 (en) 2009-10-22 2019-02-20 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
US10156559B2 (en) * 2012-12-10 2018-12-18 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
HK1250918A1 (zh) * 2015-04-06 2019-01-18 Cytoimmune Therapeutics, Inc. 用於胶质母细胞瘤的egfr导向的car疗法
EP3302197B1 (en) * 2015-05-29 2018-11-14 Koninklijke Philips N.V. Blender with a sealing gasket comprising ribs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物
WO2015105522A1 (en) 2014-01-13 2015-07-16 Forman Stephen J Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J NUCL MED MOL IMAGING，2014年08月15日，VOL:4, NR:5，PAGE(S):385 - 405，https://www.ncbi.nlm.nih.gov/pubmed/25143859
CLINICAL CANCER RESEARCH，ASSOCIATION FOR CANCER RESEARCH，2014年02月15日，VOL:20, NR:4，PAGE(S):972 - 984
PH.D THESIS，IL，ISRAELI INSTITUTE OF TECHNOLOGY，2014年05月，PAGE(S):1 - 128，https://www.researchgate.net/publication/266967998_Or_Cohen-Inbar_Recruitment_of_Immune_Effector_Cells_Against_Astrocytoma_by_MHC-Chlorotoxin_Chimeric_Proteins_Characterization_of_Melanoma_Derived_Differentiation_Antigens_in_Malignant_Astrocytomas_Ph

Also Published As

Publication number Publication date
CA3001833A1 (en) 2017-04-20
US11230577B2 (en) 2022-01-25
JP2018531015A (ja) 2018-10-25
JP7674425B2 (ja) 2025-05-09
ES2902987T3 (es) 2022-03-30
EP3362470B1 (en) 2021-09-22
US20190389917A1 (en) 2019-12-26
WO2017066481A1 (en) 2017-04-20
IL302560B1 (en) 2025-04-01
IL258670B2 (en) 2023-10-01
IL302560A (en) 2023-07-01
JP2023144018A (ja) 2023-10-06
IL258670B1 (en) 2023-06-01
PT3362470T (pt) 2021-12-10
IL258670A (en) 2018-06-28
WO2017066481A8 (en) 2017-11-23
US20220177528A1 (en) 2022-06-09
JP2022060226A (ja) 2022-04-14
CN108368159A (zh) 2018-08-03
JP7331162B2 (ja) 2023-08-22
EP3985027A1 (en) 2022-04-20
EP3362470A1 (en) 2018-08-22
DK3362470T3 (da) 2021-12-13
PL3362470T3 (pl) 2022-02-21
KR20180056780A (ko) 2018-05-29
IL302560B2 (en) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7674425B2 (ja) クロロトキシン領域を含むキメラ抗原受容体
US12497440B2 (en) CS1 targeted chimeric antigen receptor-modified T cells
JP6986190B2 (ja) ＩＬ１３Ｒα２を標的とする共刺激性キメラ抗原受容体Ｔ細胞Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
JP7297854B2 (ja) Ｐｓｃａを標的とするキメラ抗原受容体
JP2018531015A6 (ja) クロロトキシンドメインを含むキメラ抗原レセプター
JP2021192617A (ja) Ｈｅｒ２を標的とするキメラ抗原受容体
HK40063401A (en) Chimeric antigen receptors containing a chlorotoxin domain
HK40036816A (en) Chimeric antigen receptors targeted to psca

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220120

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220120

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220325

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220607

R150 Certificate of patent or registration of utility model

Ref document number: 7085990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250